Multidisciplinary Program Doubles Lung Cancer Screening Rates
Researchers have created a roadmap to improve national lung cancer screening rates that doubled lung cancer screening rates through their multidisciplinary lung cancer screening program, according to a study published in NEJM Catalyst.
Localized PI3K-Altered Colorectal Cancer: Does Low-Dose Aspirin Reduce the Risk of Recurrence?
In a Scandinavian trial (ALASCCA) reported in The New England Journal of Medicine, Martling et al found that low-dose aspirin reduced the risk of disease recurrence vs placebo in patients with PI3K-altered localized colorectal cancer.
New AACI President-Elect Selected; Two Cancer Center Leaders Join Board
Cornelia Ulrich, MS, PhD, has been elected by the members of the Association of American Cancer Institutes (AACI) to serve as Vice President/President-Elect of AACI’s Board of Directors. Dr. Ulrich is Chief Scientific Officer and Executive Director of the Comprehensive Cancer Center at Huntsman Cancer Institute at the University of Utah.
AML: Alliance Global Study Challenges Age-Based Treatment Decisions
An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group has revealed that age-based classifications in the treatment of acute myeloid leukemia (AML) may be outdated and overly simplistic. Their findings were published by Cusan et al in the journal Leukemia.
FANSS: Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?
The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United States–based lung cancer screening program dedicated to a nonsmoking population were presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Clinical Impact of Comprehensive Genomic Profiling in Early-Stage Non–Small Cell Lung CancerMore Top Stories
James R. Doty, MD, Pioneer in Neurosurgical Innovation and the Scientific Study of Compassion, Dies at 69
James R. Doty, MD James R. Doty, MD, Clinical Professor of Neurosurgery at Stanford University and a pioneer in both neurosurgical innovation and the scientific study of compassion, died on July 16, 2025. He was 69. Dr. Doty’s death occurred after prolonged hospitalization for medical...
ADC Improves Outcomes for Patients With Advanced TNBC Ineligible for Immunotherapy
Patients with an aggressive type of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody-drug conjugate (ADC) sacituzumab govitecan-hziy compared with standard chemotherapy. These...
ASCO Remembers Past President Harvey M. Golomb, MD, FASCO
ASCO is deeply saddened by the loss of past president Harvey M. Golomb, MD, FASCO, a pioneer in the study of interferon as cancer treatment. Dr. Golomb passed away on August 20, 2025; he was 82. From the beginning of his medical career, Dr. Golomb was a committed member of ASCO. He joined the...
New NIH-Funded Study Identifies Urine-Based Assay for Prostate Cancer
Researchers have developed a novel method to test for prostate cancer using biomarkers present in urine. This approach may significantly reduce the need for invasive, often painful biopsies, the researchers said in a statement. The study, which was funded in part by the National Institutes of...
Belzutifan Achieves Durable Responses Without Surgery in Advanced Pheochromocytoma/Paraganglioma
Belzutifan induced durable responses without surgery in patients with advanced pheochromocytoma or paraganglioma and demonstrated manageable safety in the phase II LITESPARK-015 trial, according to findings presented during the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract...
ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR
ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The ASCO-sponsored TAPUR study is a...
Metastatic ER-Positive, HER2-Negative Breast Cancer: Novel Treatment Combination Improves Progression-Free Survival
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full...
